Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.: A Comprehensive Revenue Analysis

Biotech Revenue Battle: Corcept vs. Travere

__timestampCorcept Therapeutics IncorporatedTravere Therapeutics, Inc.
Wednesday, January 1, 20142655100028203205
Thursday, January 1, 20155028600099892000
Friday, January 1, 201681321000133591000
Sunday, January 1, 2017159201000154937000
Monday, January 1, 2018251247000164246000
Tuesday, January 1, 2019306486000175338000
Wednesday, January 1, 2020353874000198321000
Friday, January 1, 2021365978000227490000
Saturday, January 1, 2022401858000212018000
Sunday, January 1, 2023482375000145238000
Loading chart...

Unleashing the power of data

A Decade of Growth: Corcept vs. Travere

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Corcept Therapeutics Incorporated and Travere Therapeutics, Inc. have shown remarkable trajectories. Corcept's revenue surged by an impressive 1,700% from 2014 to 2023, reflecting its strategic advancements in the pharmaceutical sector. In contrast, Travere's revenue grew by approximately 415% during the same period, showcasing its steady progress in the therapeutic landscape.

Year-on-Year Insights

Corcept's revenue growth was particularly notable between 2018 and 2023, where it increased by nearly 92%, highlighting its robust market presence. Meanwhile, Travere experienced a peak in 2021, with a revenue increase of 48% from 2014, before a slight decline in 2023. This analysis underscores the competitive nature of the biotech industry and the varying strategies companies employ to achieve financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025